PDF herunterladen
Thromb Haemost 2000; 84(06): 949-954
DOI: 10.1055/s-0037-1614154
Review Article
Schattauer GmbH

TERIMA-2: National Extension of Thrombolytic Treatment with Recombinant Streptokinase in Acute Myocardial Infarct in Cuba

The TERIMA Group of Investigators,
María Acelia Marrero-Miragaya
The authors wish to thank Dr. Julián Álvarez-Blanco and the rest of the staff from the Vice-Ministry for Science and Technology of the Public Health Ministry of Cuba and the Provincial Public Health Directions for their estimable support for this work. The Center for Genetic Engineering and Biotechnology, Havana, supplied all the streptokinase used in the trial.
Weitere Informationen

Publikationsverlauf

Received 04. Februar 2000

Accepted after resubmission 06. Juli 2000

Publikationsdatum:
13. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Aim: The extension of recombinant streptokinase (rSK) use in Cuba and to evaluate its effect on in-hospital mortality of patients with acute myocardial infarct (AMI). Methods: A phase IV clinical study was performed in 52 hospitals from the 14 Cuban provinces. Patients (any age) with ST segment elevation or bundle branch block were included if they came less than 12 h after the onset of AMI symptoms, without contraindications for thrombolytic therapy. They received 1.5 × 106 IU of rSK (Heberkinasa, Heberbiotec, Havana) intravenously, during one hour. Endpoints were death due to cardiac (pump failure, wall rupture, arrhythmia) or any cause and cardiovascular events at hospital release. Results: The study included 2923 patients, 22 – 98 years-old, 74.4% men, which represented 37.2% of the total AMI patients attended at the participating hospitals from November 1992 to May 1995. Aspirin was given to 92.5% and betablockers to 65.3%. AMI was confirmed in 93.5% of the patients. The mean symptoms – rSK infusion time interval was 5.25 h (22.3% of the patients treated within the first 3 h). 302 patients died, 80.1% of them due to cardiac causes, 12 attributed to rSK treatment, and 16 to non-cardiac causes. This 10.4% mortality represents a 4% absolute and a 28.3% relative reduction (179 lives saved per year) as compared to a survey made before rSK treatment was introduced. In a logistic regression analysis, mortality was favored by age, symptoms – infusion time, Killip class, and not having taken aspirin or betablockers. Feminine gender was close to the limit of significance. The more frequent adverse events were arrhythmias and hypotension during infusion. Major bleeding occurred in 27 patients (9 strokes). Conclusion: Local recombinant-DNA biotechnology can influence on a major health problem with favorable cost/ and risk/ benefit balances, not possible in a developing country with an imported drug. The further extension of this treatment in the country is feasible and recommended, monitored through an appropriate pharmacosurveillance program.

Key words

Streptokinase - thrombolysis - acute myocardial infarction

(Appendix, pls see pp. 952–3.)


 

  • References

  • 1 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 01: 397-401.
    PubMedGoogle Scholar
  • 2 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected AMI. ISIS-2. Lancet 1988; 02: 349-60.
    PubMedGoogle Scholar
  • 3 The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
    CrossrefPubMedGoogle Scholar
  • 4 Gruppo Italiano per lo Studio della Soppravvivenza nell’ Infarto Miocardico (GISSI-2). A factorial randomised trial of Alteplase vs Streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
    PubMedGoogle Scholar
  • 5 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
    CrossrefPubMedGoogle Scholar
  • 6 Toruncha A, Torres W, Mora E, León L, Padrón N, Castañeda M. et al. Comparative clinical trial in patients with acute myocardial infarction using recombinant and natural streptokinase. Biotecnología Aplicada 1992; 09: 289-91.
    PubMedGoogle Scholar
  • 7 Llerena L, Llerena R, Rodríguez-de la Vega A, Valdés-Rucabado JA, Fernández-Felipe R, Rodríguez-Bereau C. et al. Trombolisis intracoronaria con Estreptoquinasa Recombinante (SK-R) en el infarto agudo del miocardio. XVII Congreso Nacional de Cardiología, Guadalajara, Jalisco (México) Septiembre 29-Octubre 3. 1991
    PubMedGoogle Scholar
  • 8 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activators, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
    CrossrefPubMedGoogle Scholar
  • 9 The TERIMA Group of Investigators. Multicenter, randomised, comparative study of recombinant vs natural streptokinases in acute myocardial infarct. Thromb Haemost 1999; 82 (06) 1605-09.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Mainet D, del Rosario M, Toruncha A, Prats P, Valenzuela C, Lopez-Saura P. Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase. Fibrinolysis & Proteolysis 1998; 12 (05) 301-9.
    CrossrefPubMedGoogle Scholar
  • 11 Toruncha A, Sánchez C, López-Saura P, Pascual MA, Llerena L, Yunes P. et al. Programa Nacional de Aplicación de la Estreptoquinasa Recombinante en el infarto miocárdico agudo Informe Preliminar. Biotecnología Aplicada 1995; 12 (03) 196-7.
    PubMedGoogle Scholar
  • 12 Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Int Med 1990; 113: 949-60.
    CrossrefPubMedGoogle Scholar
  • 13 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
    PubMedGoogle Scholar
  • 14 ISIS-4 (Fourth International Study on Infarct Survival) Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
    CrossrefPubMedGoogle Scholar
  • 15 Fibrinolytic Therapy Trialists’ Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-22.
    PubMedGoogle Scholar
  • 16 EMERAS Collaborative Group. Randomized trial of late thrombolysis in patients with suspected Acute Myocardial Infarction. Lancet 1993; 342: 767-72.
    CrossrefPubMedGoogle Scholar
  • 17 Wilcox G. R. Randomized, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT) trial to investigate equivalence. Lancet 1995; 346: 329-36.
    CrossrefPubMedGoogle Scholar
  • 18 Vasilomanolakis EC, Famularo MA, Kozlowski J, Schrager B, Licht JR, Ellestad MH. Cardiac rupture following intracoronary streptokinase. Cathet Cardiovasc Diagn 1983; 09: 291-6.
    CrossrefPubMedGoogle Scholar
  • 19 Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ. et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 06: 556-85.
    CrossrefPubMedGoogle Scholar
  • 20 Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O’Keefe J. et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The primary angioplasty in myocardial infarction (PAMI) trial. J Am Coll Card 1995; 25: 370-7.
    CrossrefPubMedGoogle Scholar
  • 21 Barbash GI, Modan M, Goldbourt V, White HD, Van de Werf F. For the Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: Variation by country beyond predictive profile. J Am Coll Cardiol 1993; 21: 281-6.
    CrossrefPubMedGoogle Scholar
  • 22 White HD. Lifting the smoke-screen: The enigma of better outcome in smokers after myocardial infarction. Am J Cardiol 1995; 75: 278-9.
    CrossrefPubMedGoogle Scholar
  • 23 Maggioni AP, Franzosi MG, Malacrida R, Tognoni G. On behalf of the GISSI Investigators Perspectives on therapeutic Interventions in Patients with Acute Myocardial Infarction: Viewpoints after the GISSI-2 Results. Clin Cardiol 1991; 14: 549-56.
    PubMedGoogle Scholar
  • 24 Barbash GI, White HD, Modan M, Van de Werf F. For the investigators of the International Tissue Plasminogen Activator/Streptokinase Trial Antecedent Angina Pectoris Predicts Worse Outcome after myocardial infarction in patients receiving thrombolytic therapy: Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1992; 20: 36-41.
    CrossrefPubMedGoogle Scholar
  • 25 Carabello BA, Spaan JF. Thrombolytic therapy in acute myocardial infarction. In: Comerota AJ. (Ed) Thrombolytic Therapy, Grune &. Stratton Inc: Orlando; 1988: 165-87.
    Google Scholar
  • 26 National Statistics Direction, Ministry for Public Health. Statistics Yearbook: Havana; 1999